NasdaqGS - Nasdaq Real Time Price USD

Verve Therapeutics, Inc. (VERV)

4.4900

-0.0200

(-0.44%)

As of 10:59:21 AM EDT. Market Open.

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News

BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.

Zacks 21 hours ago

VERV
-0.44%
CELG-RT

IRWD
Why Verve Therapeutics Is Skyrocketing Today

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy.

Motley Fool yesterday

VERV
-0.44%
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.

Zacks yesterday

VERV
-0.44%
LLY
Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Over the last 7 days, the United States market has risen 6.8%, and over the past 12 months, it is up 5.9%, with earnings forecasted to grow by 14% annually. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value in such a buoyant market environment. By focusing on stocks with strong financial foundations and clear growth potential, investors may uncover opportunities that balance risk with promising...

Simply Wall St. 2 days ago

UAMY

VERV
-0.44%
CLOV
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Pharmaceutical Technology 2 days ago

LLY

VERV
-0.44%
This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped Monday.

Barrons.com 2 days ago

VERV
-0.44%
LLY
Top Premarket Gainers

Third Harmonic Bio (THRD) shares rose 40% in recent Monday premarket activity, after saying its boar

PREMIUM
MT Newswires 3 days ago

AAPL

THRD

VERV
-0.44%
Verve’s second swing at gene editing for heart disease shows early promise

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety concerns — at least so far.

BioPharma Dive 3 days ago

VERV
-0.44%
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second

GlobeNewswire 3 days ago

VERV
-0.44%
Sector Update: Health Care Stocks Mixed Premarket Friday

Health care stocks were mixed premarket Friday with the Health Care Select Sector SPDR Fund (XLV) wa

PREMIUM
MT Newswires 6 days ago

NVS

VERV
-0.44%
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 is the company’s novel, in vivo, investigational base editing medic

GlobeNewswire 6 days ago

VERV
-0.44%
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options t

GlobeNewswire 12 days ago

VERV
-0.44%
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 15 days ago

GLPG

GLPGF

PTCT
Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]

Insider Monkey 16 days ago

VERV
-0.44%
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent DirectorsWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Boar

GlobeNewswire 16 days ago

VERV
-0.44%
IUGNF

ABOS
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing

GlobeNewswire 24 days ago

VERV
-0.44%
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations

Verve Therapeutics ( NASDAQ:VERV ) Full Year 2024 Results Key Financial Results Revenue: US$32.3m (up 175% from FY...

Simply Wall St. last month

VERV
-0.44%
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 19.44% and 90.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

VERV
-0.44%
Verve Therapeutics: Q4 Earnings Snapshot

The Boston-based company said it had a loss of 58 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.

Associated Press Finance last month

VERV
-0.44%
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 VERVE-102 has been well-tolerated, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed Delivery of opt-in package to Eli Lilly and an opt-in decision from Lilly expected in the second half of 2025 Enrollment ongoing in Pulse-1 Phase 1b clinical trial of VER

GlobeNewswire last month

VERV
-0.44%

Performance Overview

Return	VERV	S&P 500 (^GSPC)
YTD	-20.39%	-10.44%
1-Year	-33.38%	+4.89%
3-Year	-77.91%	+19.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Verve Therapeutics, Inc. (VERV)

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News

Why Verve Therapeutics Is Skyrocketing Today

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.

Top Premarket Gainers

Verve’s second swing at gene editing for heart disease shows early promise

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Sector Update: Health Care Stocks Mixed Premarket Friday

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biotech stocks slide as Marks resignation seen being negative for sector

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

Verve Therapeutics: Q4 Earnings Snapshot

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Performance Overview